Evidence map›Paper›PMID 42400017›Full record

ArticleThrombosis journal2026

The PH score: a practical tool for screening myeloproliferative neoplasms in acute portal vein thrombosis.

Hikmet Öztop, Nevriye Gül Ada Tak, Fatih Eren, Fazıl Çağrı Hunutlu, Gökhan Ocakoğlu

Abstract read
In one paragraph

Article in Thrombosis journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hikmet ÖztopDepartment of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Gorukle Campus, Bursa, Turkey. hikmetoztop@uludag.edu.tr.ORCID http://orcid.org/0000-0002-0199-3791
Nevriye Gül Ada TakDepartment of Internal Medicine, Buyukorhan State Hospital, Bursa, Turkey.
Fatih ErenDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey.
Fazıl Çağrı HunutluDivision of Hematology, Department of Internal Medicine, University of Health Sciences, Bursa Sehir Training and Research Hospital, Bursa, Turkey.
Gökhan OcakoğluDepartment of Biostatistics, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Portal vein thrombosis (PVT) is a rare but clinically significant condition often associated with myeloproliferative neoplasms (MPNs). Diagnosing MPNs in acute PVT may be difficult, particularly in the absence of overt hematologic abnormalities. We retrospectively analyzed 93 patients with acute PVT from January 2009 to June 2024, excluding those with chronic thrombosis or previously established systemic diseases. MPNs were identified in 23 patients (24.7%). Hemoglobin (Hb), platelet count (Plt) and inflammatory indices (PLR, SII, and PIV) were associated with MPNs in univariate analyses (p < 0.05), while Hb and Plt were retained as independent predictors in a parsimonious multivariable logistic regression model. Based on these parameters, the PH score was developed: PH = (0.510 × Hb) + (0.006 × Plt) - 9.470. The model demonstrated acceptable discriminative performance, with an apparent AUC of 0.864 in the training cohort and an AUC of 0.820 on internal validation in the overall cohort, using an optimal cut-off value of - 1.016. The PH score may act as a straightforward laboratory tool to aid in early risk stratification for patients with acute PVT, complementing, but not replacing, the standard diagnostic evaluation.

Indexed as

HemoglobinJAK2 mutationMyeloproliferative neoplasmsPlatelet countPortal veinThrombosis

Identifiers

PMID42400017
PMCPMC13334748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.